 study cyproheptadine treatment metastatic carcinoid tumor malignant carcinoid syndrome Sixteen patients metastatic neuroendocrine tumors malignant carcinoid syndrome cyproheptadine Periactin Merck Sharp Dohme West Point PA maximum tolerable doses mg Usual side effects mild sedation dry mouth patients impossible treatment due nausea vomiting patients significant relief diarrhea weight gain Relief flushing uncommon therapeutic benefit cyproheptadine peripheral effect acid excretion patients case reports objective tumor regression cyproheptadine therapy patients Cyproheptadine useful therapeutic tool management diarrhea malignant carcinoid syndrome appropriate initial total daily dose mg/kg fractions prompt modification minimal tolerable side effects